Stephen Saad’s Aspen completes $1.7 billion APAC exit to cut debt

Aspen Pharmacare Holdings, the South Africa–based multinational drugmaker led by billionaire Stephen Saad, has completed the divestment of its Asia-Pacific business, securing proceeds of about R27 billion ($1.7 billion) in a move that strengthens its balance sheet and sharpens its strategic focus.

The JSE-listed group confirmed that all conditions tied to the transaction were fulfilled, with the deal closing on May 29, 2026, marking the final step in a process first announced in late 2025.

Unlocking value, strengthening balance sheet

The transaction was completed at a total consideration of AUD 2.37 billion ($1.7 billion), unchanged from initial terms, with no adjustments at closing. Aspen said transaction-related costs came in at less than 5% of the deal value, in line with earlier guidance.

Following currency hedging at more favorable rates than initially projected, the group’s net proceeds rose to approximately R27 billion ($1.7 billion), above the roughly R25 billion ($1.54 billion) estimate outlined at the time of the deal announcement. The bulk of the proceeds has been deployed toward reducing group debt, reinforcing Aspen’s balance sheet and improving financial flexibility as it positions for future growth.

Strategic reset after APAC exit

The divestment marks a decisive shift in Aspen’s portfolio, following the sale of its Asia-Pacific operations, excluding China, to private equity firm BGH Capital.

The business included operations across Australia, New Zealand, Hong Kong, Malaysia, Taiwan, and the Philippines, alongside associated intellectual property assets.

While Aspen had not initially planned to exit the region, the company moved ahead after receiving an unsolicited offer, with the board determining the valuation represented compelling value for shareholders.

Positioning for growth and capital returns

Founded in 1997 and headquartered in Durban, Aspen Pharmacare has grown into a leading global specialty pharmaceutical company. It remains the largest drug manufacturer in Africa and a dominant player in the South African market. Saad, who has led the company since 1999, owns 13.2% of Aspen, or 58.8 million shares, making him the largest shareholder.

Aspen said the strengthened balance sheet enhances its ability to pursue capital allocation opportunities, including potential share buybacks, as it seeks to unlock further shareholder value.

The company also noted that its current share price does not fully reflect the intrinsic value of its remaining operations and future earnings potential, particularly following the improvement in its financial position. With reduced leverage and increased flexibility, Aspen is now better positioned to focus on its core growth markets and high-margin segments, as it reshapes its portfolio for long-term returns.